A recent study on Huonslab’s Hydiffuze technology has found that the pharmaceutical product demonstrated enhanced bioavailability of subcutaneous infliximab has been selected as a poster presentation ...

MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway.

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Eagle Pharmaceuticals (EGRX) announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds ...

Under the terms of the agreement, Eagle will receive $69 million before transaction costs as an upfront payment in exchange for a prespecified amount of Eagle’s royalty interest for net sales of ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...